HER2-positive breast cancer with brain metastases
The brain is the weak point of HER2-positive breast cancer: antibodies control the rest of the body but cross poorly into the brain, so up to half of patients with advanced disease develop brain metastases. Tucatinib with trastuzumab and capecitabine was the first drug proven to help, and trastuzumab deruxtecan shrinks brain lesions in most patients.
Overview
Brain metastases became the signature problem of HER2-positive disease once trastuzumab began to control it elsewhere: antibodies are too large to cross an intact blood-brain barrier, so the brain was often the first and only site of progression. Lesions present with headache, seizures or focal deficits, or are found on staging MRI; guidelines do not recommend routine screening MRI, though the landmark trials required it. Local treatment follows the number and size of lesions: stereotactic radiosurgery for a limited number, which the Alliance N0574 trial showed preserves cognition better than adding whole-brain radiotherapy, surgery for a large symptomatic lesion, and whole-brain radiotherapy held back for many lesions or leptomeningeal spread.
HER2CLIMB was the first randomised trial to enrol patients with active, untreated brain metastases and prove a drug helps them. It randomised 612 women who had received trastuzumab, pertuzumab and trastuzumab emtansine, almost half with brain metastases, to tucatinib or placebo with trastuzumab and capecitabine: progression-free survival rose from 5.6 to 7.8 months (hazard ratio 0.54), overall survival from 17.4 to 21.9 months (hazard ratio 0.66), and the risk of intracranial progression fell by about two thirds, leading to approval in April 2020. Earlier, lapatinib with capecitabine had shown intracranial responses in the single-arm LANDSCAPE study, and neratinib reduced the need for brain interventions in NALA; HER2CLIMB-02 later added tucatinib to trastuzumab emtansine with a modest gain concentrated in patients with brain disease, and HER2CLIMB-05 in 2025 showed tucatinib added to first-line antibody maintenance delays progression by more than eight months.
Trastuzumab deruxtecan then showed that an antibody-drug conjugate can work inside the brain. Small phase 2 studies (TUXEDO-1, DEBBRAH) reported high intracranial response rates, and DESTINY-Breast12 treated 504 patients, 263 with brain metastases, with an intracranial objective response in 71.7 percent and 61.6 percent of the brain-metastasis cohort progression-free at twelve months, including patients whose lesions had not been irradiated. Because trastuzumab deruxtecan is also the second-line standard after DESTINY-Breast03, and first line with pertuzumab after DESTINY-Breast09, many patients now receive brain-active systemic therapy before the brain is ever involved. Whether systemic therapy should replace radiotherapy first in selected asymptomatic patients, how to treat leptomeningeal disease, and the risk of radionecrosis when radiosurgery and antibody-drug conjugates are combined are the open questions.
State of the art
- Trastuzumab deruxtecan achieves intracranial responses in most patients, including untreated lesions.
- Radiosurgery has replaced whole-brain radiotherapy for limited disease, preserving cognition.
- Brain-metastasis cohorts are now written into first-line HER2 trials rather than excluded.
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- HER2CLIMB proved a systemic drug can extend survival in patients with active brain metastases, and it changed trial eligibility rules across oncology.
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowFainting or palpitations
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
- Emergency services nowSkin reaction
Blisters, peeling, or sores in the mouth or eyes with a rash. Enfortumab vedotin carries a boxed warning for Stevens-Johnson syndrome and toxic epidermal necrolysis, mostly in the first cycle.
- Emergency services nowBleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
- Emergency services nowBlood clot (lenalidomide, pomalidomide, thalidomide)
A swollen painful calf, or sudden breathlessness with chest pain; venous and arterial thromboembolism is a boxed warning and blood-thinning prophylaxis is recommended.
- Call the 24-hour line nowInterstitial lung disease or pneumonitis
Any new or worsening cough, breathlessness or fever. The label says to interrupt treatment for any suspected ILD and to permanently discontinue for grade 2 or higher.
- Check before combiningLapatinib with Tucatinib: major interaction
CYP3A4: Tucatinib (strong inhibitor) raises Lapatinib exposure (sensitive substrate).. Avoid; if unavoidable, reduce to 500 mg daily.
See all on the product pages:CapecitabineLapatinibNeratinibTrastuzumab deruxtecanTrastuzumab emtansineTucatinib·Printable cards in the navigator
Anatomy and lymph node drainage
- Ducts (most cancers start here)
- Lobules (lobular carcinoma; phyllodes tumours arise from the surrounding stroma)
- Upper outer quadrant (commonest site)
- Nipple-areola
- Nodes: axillary level I
- Nodes: axillary level II-III
- Nodes: internal mammary
- Nodes: supraclavicular
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
- Ducts (most cancers start here)Asymptomatic HER2-positive brain metastases found on staging MRI (systemic therapy first under study) · Active or progressing HER2-positive brain metastases (HER2CLIMB population) · Stable, previously irradiated HER2-positive brain metastases · Leptomeningeal disease from HER2-positive breast cancer · Oligometastatic HER2-positive brain disease treated with stereotactic radiosurgery · HER2-positive brain metastases without extracranial progression
- Lobules (lobular carcinoma; phyllodes tumours arise from the surrounding stroma)
- Upper outer quadrant (commonest site)
- Nipple-areola
- axillary level I
- axillary level II-III
- internal mammary
- supraclavicular
Same organ: Triple-negative breast cancer (TNBC), Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast
Up to half of women with metastatic HER2-positive breast cancer develop brain metastases during their illness, more than in any other breast subtype, partly because HER2 antibodies control disease elsewhere while the brain remains a sanctuary.
- MRIStandard of care
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Stereotactic radiosurgery to each lesion, or surgery for a large symptomatic lesion, followed by HER2-directed systemic therapy; whole-brain radiotherapy reserved for many lesions.
Tucatinib with trastuzumab and capecitabine (HER2CLIMB), which improved survival and delayed brain progression.
Trastuzumab deruxtecan, with intracranial responses in most patients (DESTINY-Breast12), positioned as second-line therapy after DESTINY-Breast03.
Tucatinib added to trastuzumab and pertuzumab maintenance after induction chemotherapy (HER2CLIMB-05).
Neratinib or lapatinib with capecitabine, trastuzumab emtansine with tucatinib (HER2CLIMB-02), repeat radiosurgery, or a clinical trial.
Subtypes & biomarkers
top- Asymptomatic HER2-positive brain metastases found on staging MRI (systemic therapy first under study)
- Active or progressing HER2-positive brain metastases (HER2CLIMB population)
- Stable, previously irradiated HER2-positive brain metastases
- Leptomeningeal disease from HER2-positive breast cancer
- Oligometastatic HER2-positive brain disease treated with stereotactic radiosurgery
- HER2-positive brain metastases without extracranial progression
- HER2 status on the primary or an extracranial metastasis (brain biopsy rarely needed)
- Contrast-enhanced brain MRI at baseline and every six to twelve weeks on treatment
- Number, size and location of lesions (radiosurgery versus whole-brain radiotherapy)
- Hormone receptor status
- Cerebrospinal fluid cytology when leptomeningeal disease is suspected
- Neurological performance status and corticosteroid requirement
How often this target appears
- 2003Brain as the first site of progression on trastuzumab described
- 2013LANDSCAPE: lapatinib with capecitabine shrinks untreated brain metastases
- 2016Alliance N0574: radiosurgery alone preserves cognition better than adding whole-brain radiotherapy
- 2020HER2CLIMB: tucatinib approved, the first drug proven in active brain metastases
- 2022TUXEDO-1 and DEBBRAH: trastuzumab deruxtecan active in the brain
- 2023HER2CLIMB-02: tucatinib with trastuzumab emtansine
- 2024DESTINY-Breast12: intracranial response in most patients
- 2025HER2CLIMB-05: tucatinib in first-line maintenance
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 15 changes by month →- 2026-09-17This recordHER2-positive breast cancer with brain metastasesFacts on this page last checked
When this page itself was last checked or edited.
- 2025Trial resultHER2CLIMB-05HER2CLIMB-05 reported
PFS 24.
- 2025MilestoneHER2CLIMB-05HER2CLIMB-05: tucatinib in first-line maintenance
A milestone in how this cancer is treated.
- 2024Trial resultDESTINY-Breast12DESTINY-Breast12 reported
CNS ORR 71.
- 2024MilestoneDESTINY-Breast12DESTINY-Breast12: intracranial response in most patients
A milestone in how this cancer is treated.
- 2023Trial resultHER2CLIMB-02HER2CLIMB-02 reported
PFS 9.
What is in development for HER2-positive breast cancer with brain metastases, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Technologies being tested · 1
Trials reported · 4
- HER2CLIMB-05 · phase 3 · 2025 · positive
- DESTINY-Breast12 · phase 3 · 2024 · positive
- HER2CLIMB · phase 2 · 2019 · positive
- HER2CLIMB-02 · phase 3 · 2023 · mixed
Combinations being explored · 1
Ideas not yet in a trial · 1
Open problems and what is being done
No randomised trial has compared systemic therapy first with radiosurgery first for asymptomatic lesions.
Leptomeningeal disease still has no proven treatment.
and how the field plans to fix it →What is being done about thisAdvanced and metastatic diseaseAvailable now- MRIStandard of care
- Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)Established
- Trastuzumab deruxtecanApproved
- TucatinibApproved
In trials- Alliance N0574 (NCCTG N0574)Positive
- DESTINY-Breast12Positive
- HER2 PETPhase 2
- HER2CLIMBPositive
- HER2CLIMB-02Mixed
Ideas and roadmapsBackground: HER2-positive brain metastases. Also on OnCo: Atlas of advanced disease · Invasion and metastasis.
Radionecrosis after radiosurgery may be commoner with antibody-drug conjugates.
Screening MRI might find lesions earlier but no trial shows it helps.
and how the field plans to fix it →What is being done about thisFinding cancer earlierAvailable now- MRIStandard of care
In trialsNothing recorded yet.
Ideas and roadmapsNothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Expert centres
topExpert centres
Houston · cancer center | United States | 0 | 6,724 | 95,007 | #2 | ||
Seoul · hospital | South Korea | none recorded | 0 | 1,312 | 17,172 | #3 | |
Rochester, MN · hospital | United States | 0 | 4,511 | 44,748 | #5 | ||
Villejuif · cancer center | France | none recorded | 0 | 1,855 | 31,182 | #6 | |
Seoul · hospital | South Korea | none recorded | 0 | 1,607 | 24,676 | #8 | |
Baltimore · cancer center | United States | 0 | 2,955 | 41,449 | #10 | ||
Berlin · university | Germany | none recorded | 0 | 1,563 | 17,749 | #12 | |
Tokyo · government | Japan | none recorded | 0 | 1,599 | 21,937 | none recorded | #13 |
Boston · hospital | United States | 0 | 3,582 | 54,857 | #16 | ||
Cleveland · hospital | United States | 0 | 2,264 | 29,412 | #20 | ||
Seoul · hospital | South Korea | none recorded | 0 | 464 | 3,248 | #22 | |
Barcelona · cancer center | Spain | none recorded | 1 | 966 | 23,221 | none recorded | #28 |
Stanford · university | United States | 0 | 3,000 | 50,162 | #30 | ||
San Francisco · cancer center | United States | 0 | 2,800 | 46,704 | #33 | ||
Stockholm · university | Sweden | none recorded | 0 | 987 | 12,440 | #39 |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with HER2-positive breast cancer with brain metastases but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about HER2-positive breast cancer with brain metastases
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example HER2 status on the primary or an extracranial metastasis, Contrast-enhanced brain MRI at baseline and every six to twelve weeks on treatment, Number, size and location of lesions, Hormone receptor status, Cerebrospinal fluid cytology when leptomeningeal disease is suspected), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Asymptomatic HER2-positive brain metastases found on staging MRI, Active or progressing HER2-positive brain metastases, Stable, previously irradiated HER2-positive brain metastases.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Limited brain metastases at first presentation
- For my situation (limited brain metastases at first presentation), which of the standard options do you recommend and why?Why: Guideline options include: Stereotactic radiosurgery to each lesion, or surgery for a large symptomatic lesion, followed by HER2-directed systemic therapy; whole-brain radiotherapy reserved for many lesions.
- How do the results of Alliance N0574 (NCCTG N0574) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Active brain metastases after trastuzumab, pertuzumab and trastuzumab emtansine
- For my situation (active brain metastases after trastuzumab, pertuzumab and trastuzumab emtansine), which of the standard options do you recommend and why?Why: Guideline options include: Tucatinib with trastuzumab and capecitabine (HER2CLIMB), which improved survival and delayed brain progression.
- Am I a candidate for Tucatinib, Trastuzumab, Capecitabine, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Brain metastases, stable or active, second line
- For my situation (brain metastases, stable or active, second line), which of the standard options do you recommend and why?Why: Guideline options include: Trastuzumab deruxtecan, with intracranial responses in most patients (DESTINY-Breast12), positioned as second-line therapy after DESTINY-Breast03.
- Am I a candidate for Trastuzumab deruxtecan, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DESTINY-Breast12 and DESTINY-Breast03 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
First-line maintenance to delay brain progression
- For my situation (first-line maintenance to delay brain progression), which of the standard options do you recommend and why?Why: Guideline options include: Tucatinib added to trastuzumab and pertuzumab maintenance after induction chemotherapy (HER2CLIMB-05).
- Am I a candidate for Tucatinib, Trastuzumab, Pertuzumab, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB-05 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Later lines
- For my situation (later lines), which of the standard options do you recommend and why?Why: Guideline options include: Neratinib or lapatinib with capecitabine, trastuzumab emtansine with tucatinib (HER2CLIMB-02), repeat radiosurgery, or a clinical trial.
- Am I a candidate for Neratinib, Lapatinib, Capecitabine or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB-02 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Any stage
- Are there clinical trials I could join, for example of Trastuzumab deruxtecan, Tucatinib, HER2CLIMB-05, Systemic-first management of HER2-positive brain metastases?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “No randomised trial has compared systemic therapy first with radiosurgery first for asymptomatic lesions”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Leptomeningeal disease still has no proven treatment”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Newly diagnosed? Read the first 60 days with HER2-positive breast cancer with brain metastases, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
10targets
3drugs
11companies
12terms
4trials
6pairings
1ideas
1bottlenecks
1Latest papers
topQuery for this cancer: (TITLE:"HER2-positive breast cancer with brain metastases" OR ABSTRACT:"HER2-positive breast cancer with brain metastases" OR TITLE:"HER2-positive brain metastases" OR ABSTRACT:"HER2-positive brain metastases" OR TITLE:"Central nervous system metastases from HER2-positive breast cancer" OR ABSTRACT:"Central nervous system metastases from HER2-positive breast cancer" OR TITLE:"Intracranial HER2-positive disease" OR ABSTRACT:"Intracranial HER2-positive disease") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about HER2-positive breast cancer with brain metastases, not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerEarly HER2-positive breast cancer
Shares HER2 PET, Zanidatamab, Trastuzumab rezetecan, Trastuzumab emtansine and the tag subtype-page.
- CancerHER2-low and HER2-ultralow metastatic breast cancer
Shares HER2 PET, Trastuzumab rezetecan, Trastuzumab, Trastuzumab deruxtecan and the tag subtype-page.
- CancerInflammatory breast cancer
Shares Trastuzumab emtansine, Pertuzumab, Capecitabine, Trastuzumab and the tag subtype-page.
- CancerHER2-amplified colorectal cancer
Shares Zanidatamab, Tucatinib, Pertuzumab, Trastuzumab and the tag subtype-page.
- CancerHER2-positive gastric cancer
Shares Zanidatamab, Capecitabine, Trastuzumab, Trastuzumab deruxtecan and the tag subtype-page.
- CancerMucinous ovarian cancer
Shares Capecitabine, Trastuzumab, Trastuzumab deruxtecan and the tag subtype-page.
- CancerExtrahepatic cholangiocarcinoma (perihilar and distal)
Shares Zanidatamab, Capecitabine, MRI, Trastuzumab deruxtecan and the tag subtype-page.
- CancerMetastatic triple-negative breast cancer
Shares Brain metastases (intracranial disease), Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Capecitabine, Trastuzumab deruxtecan and the tag subtype-page.